Asset profile
CFI-400945
Unknown / undisclosed
Evidence outlook · lead readout
NCT03187288 · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Relapsed Cancer, Refractory Cancer
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT03187288: This was a single-arm, open-label study: every participant received CFI-400945 with no placebo or comparator treatment and no blinding, so it cannot show whether the drug works better than another option. The main goals were tolerated dose and safety, and results have not yet been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
December 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.